Enhanced Octreotide Delivery Systems for Acromegaly Treatment

This inventive concept improves the treatment of acromegaly by introducing novel oral formulations, monitoring devices, and personalized treatment approaches that enhance the efficacy, safety, and efficiency of octreotide delivery.

The original patent relates to oral drug delivery of octreotide for treating acromegaly. However, the existing patent has limitations in maintaining therapeutic levels of octreotide, predicting and adjusting dosage, and reducing side effects. This inventive concept addresses these limitations by introducing controlled-release formulations, machine learning algorithms, and co-administration of gut-friendly probiotics.

The inventive concept comprises four key aspects: 1) controlled-release oral formulations of octreotide designed to maintain therapeutic levels for an extended period; 2) a monitoring device for tracking IGF-1 levels and clinical symptoms; 3) machine learning algorithms for predicting and adjusting dosage based on individual patient responses; and 4) co-administration of gut-friendly probiotics to reduce side effects. These components work in tandem to provide personalized, efficient, and safe treatment of acromegaly.

The new claims introduce novel and non-obvious improvements over the original patent, including the use of controlled-release formulations, machine learning algorithms, and gut-friendly probiotics. These innovations provide a significant enhancement in the treatment of acromegaly, making the inventive concept a substantial improvement over the existing patent.

Alternative embodiments of the inventive concept could include different types of controlled-release formulations, such as nanoparticles or liposomes, or the use of wearable devices for real-time monitoring. Additionally, the inventive concept could be adapted for treatment of other diseases beyond acromegaly, such as diabetes or cancer.

The enhanced octreotide delivery systems have significant commercial potential in the pharmaceutical industry, particularly in the areas of rare diseases and personalized medicine. The target market includes pharmaceutical companies, hospitals, and research institutions focused on developing innovative treatments for acromegaly and other diseases.